Through continued revenue growth, prudent allocation of resources, and disciplined expense management, we expect to hit the cash flow break-even point before year-end. This milestone should demonstrate to our shareholders that we can be a growing, self-sustaining biopharmaceutical company without the need for additional equity capital to fund our operations.

Aug 8, 2023 / CEO / receipt, needs a key / Paul Edith, CEO | earnings call 2023-08-08 | transcript 6be6cd59-6535-4430-bf41-03814aef575b | chars 14411-14771 | segment 14